Ethris has partnered Lonza for the development of room-temperature stable mRNA vaccine candidates targeting respiratory ...
The FDA has granted clearance to CureVac's IND for the open-label Phase I trial of CVHNLC in individuals with sqNSCLC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback